The ubiquitin proteolytic system and pathogenesis of human diseases: a novel platform for mechanism-based drug targeting

被引:91
|
作者
Ciechanover, A [1 ]
机构
[1] Technion Israel Inst Technol, Dept Biochem, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel
[2] Technion Israel Inst Technol, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel
关键词
cancer; neurodegeneration; protein degradation; proteasome; ubiquitin;
D O I
10.1042/BST0310474
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Until the early 1980s, protein degradation was a neglected research area, and scientists were mostly busy deciphering the genetic code and its translation to the proteome. Destruction of cellular proteins was thought to be a scavenger, non-specific and dead-end process. Although it was known that proteins do turn over, the large extent and high specificity of the process, whereby distinct proteins have half-lives that range from a few minutes to several days, was not appreciated. The discovery of the lysosome by Christian de Duve did not change this view significantly, as it was clear that this organelle is involved mostly in the degradation of extracellular proteins, and their proteases cannot be substrate-specific. The discovery of the complex cascade of the ubiquitin pathway revolutionized the field. it is clear now that degradation of cellular proteins via the ubiquitin system is a highly complex, temporally controlled and tightly regulated process that plays major roles in a variety of basic pathways and processes during cell life and death, and in health and disease. The system is involved in targeting many cellular proteins, among them cell cycle regulators, growth- and differentiation-controlling factors, transcriptional activators, cell-surface receptors and ion channels, endoplasmic reticulum proteins, antigenic proteins destined for presentation on class I MHC molecules, and abnormal/misfolded proteins. Consequently, it is involved in regulating many basic cellular processes, such as cell cycle and division, growth and differentiation, signal transduction and transcription, modulation of the secretory and endocytic pathways, the immune and inflammatory responses, and quality control. With the multitude of substrates targeted and the numerous processes involved, it is not surprising that aberrations in the pathway have been implicated in the pathogenesis of many diseases, with certain malignancies and neurodegenerative disorders being ranked among them.
引用
收藏
页码:474 / 481
页数:8
相关论文
共 50 条
  • [1] The ubiquitin system: pathogenesis of human diseases and drug targeting
    Ciechanover, A
    Schwart, AL
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2004, 1695 (1-3): : 3 - 17
  • [2] The ubiquitin proteolytic system: from basic mechanisms through human diseases and onto drug targeting
    Ciechanover, A.
    [J]. FEBS JOURNAL, 2006, 273 : 1 - 1
  • [3] The ubiquitin proteolytic system: From basic mechanisms through human diseases and onto drug targeting
    Ciechanover, Aaron
    [J]. PLACENTA, 2008, 29 (08) : A2 - A2
  • [4] The ubiquitin proteolytic system - From a vague idea, through basic mechanisms, and onto human diseases and drug targeting
    Ciechanover, A
    [J]. NEUROLOGY, 2006, 66 : S7 - S19
  • [5] The ubiquitin proteolytic system - from basic mechanisms thru human diseases and onto drug development
    Ciechanover, A.
    [J]. FEBS JOURNAL, 2011, 278 : 12 - 12
  • [6] Targeting the ubiquitin system by fragment-based drug discovery
    Kennedy, Cassandra
    McPhie, Katherine
    Rittinger, Katrin
    [J]. FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 9
  • [7] Pathogenesis of Human Mitochondrial Diseases Is Modulated by Reduced Activity of the Ubiquitin/Proteasome System
    Segref, Alexandra
    Kevei, Eva
    Pokrzywa, Wojciech
    Schmeisser, Kathrin
    Mansfeld, Johannes
    Livnat-Levanon, Nurit
    Ensenauer, Regina
    Glickman, Michael H.
    Ristow, Michael
    Hoppe, Thorsten
    [J]. CELL METABOLISM, 2014, 19 (04) : 642 - 652
  • [8] PREDICTION OF HUMAN DRUG-DRUG INTERACTIONS FROM MECHANISM-BASED INHIBITION IN HUMAN HEPATOCYTES
    Xu, Lilly
    Chen, Yuping
    Pan, Yvonne
    Skiles, Gary
    Shou, Magang
    [J]. DRUG METABOLISM REVIEWS, 2007, 39 : 127 - 128
  • [9] Novel genomic methods for drug discovery and mechanism-based toxicological assessment
    Gant, Timothy W.
    Zhang, Shu-Dong
    Taylor, Emma L.
    [J]. CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2009, 12 (01) : 72 - 80
  • [10] Mechanism-Based Targeting of Sickle Cell Pathobiology and Pain with Novel Transdermal Curcumin
    Goel, Yugal
    Arellano, Mya Angela
    Fouda, Raghda T.
    Kerr, Daniel
    Jana, Sirsendu
    Lomeli, Reina Alexis
    Velasco, Graham J.
    Banerjee, Probal
    Argueta, Donovan Alexander
    Gupta, Mihir
    Prince, Richard
    Alayash, Abdu
    Friedman, Joel
    Gupta, Kalpna
    [J]. BLOOD, 2023, 142